Through the lens of public health genomics, this article probes certain issues that concern the evaluation of diagnostic tests and molecular biomarkers, and the accompanying policy and regulatory implications. It begins with some conceptual remarks followed by a discussion of evaluation, translation, and regulation, and their importance for public health.
No takes yet. Share an insight, caveat, or question.
R.L. Zimmern (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: